In a first for the UK, an investment fund dedicated to psychedelic healthcare has been launched.
The new fund comes as recent rigorous clinical trials have demonstrated psychedelics’ potential to treat unmet needs in mental illnesses, including post-traumatic stress disorder (PTSD), depression, addiction, and anxiety.
It has been launched by London-based Venture Capital Neo Kuma Ventures which has already attracted millions of pounds in investment, has no set cap and will continue to draw venture capital through the first half of 2021.
Read More
UK’s first investment fund dedicated to psychedelic healthcare
